The firm recorded $58 million in sales for the autologous TIL therapy, which it is working on moving into earlier melanoma settings and other tumor types.

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...